190 related articles for article (PubMed ID: 28045603)
1. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
4. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
Wahl DR; Stenmark MH; Tao Y; Pollom EL; Caoili EM; Lawrence TS; Schipper MJ; Feng M
J Clin Oncol; 2016 Feb; 34(5):452-9. PubMed ID: 26628466
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
[TBL] [Abstract][Full Text] [Related]
6. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?
Landman MP; Feurer ID; Pinson CW; Moore DE
HPB (Oxford); 2011 Nov; 13(11):783-91. PubMed ID: 21999591
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
[TBL] [Abstract][Full Text] [Related]
8. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis.
Seo YS; Kim MS; Yoo HJ; Jang WI; Paik EK; Han CJ; Lee BH
Cancer Med; 2016 Nov; 5(11):3094-3101. PubMed ID: 27709795
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
11. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma.
Naugler WE; Sonnenberg A
Liver Transpl; 2010 Oct; 16(10):1186-94. PubMed ID: 20879017
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Leung HW; Liu CF; Chan AL
Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis.
Bi N; Shedden K; Zheng X; Kong FS
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1378-1390. PubMed ID: 27479723
[TBL] [Abstract][Full Text] [Related]
14. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.
Cadier B; Bulsei J; Nahon P; Seror O; Laurent A; Rosa I; Layese R; Costentin C; Cagnot C; Durand-Zaleski I; Chevreul K;
Hepatology; 2017 Apr; 65(4):1237-1248. PubMed ID: 28176349
[TBL] [Abstract][Full Text] [Related]
15. Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer.
Tramontano AC; Cipriano LE; Kong CY; Shepard JA; Lanuti M; Gazelle GS; McMahon PM
AJR Am J Roentgenol; 2013 May; 200(5):1020-7. PubMed ID: 23617484
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.
Thein HH; Isaranuwatchai W; Qiao Y; Wong K; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
Cancer Med; 2017 Sep; 6(9):2017-2033. PubMed ID: 28791798
[TBL] [Abstract][Full Text] [Related]
17. Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis.
Zhang H; Chang N; Han T; Ma S; Qu G; Liu H; Sun C; Cheng C; Zhou Q; Sun Y
Future Oncol; 2021 Oct; 17(30):4027-4040. PubMed ID: 34278818
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
19. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Rajyaguru DJ; Borgert AJ; Smith AL; Thomes RM; Conway PD; Halfdanarson TR; Truty MJ; Kurup AN; Go RS
J Clin Oncol; 2018 Feb; 36(6):600-608. PubMed ID: 29328861
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of navigated radiofrequency ablation for hepatocellular carcinoma in China.
Lai Y; Li K; Li J; Liu SX
Int J Technol Assess Health Care; 2014 Oct; 30(4):400-8. PubMed ID: 25682956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
